This clinical trial focuses on patients with ulcerative colitis, a chronic inflammatory bowel disease that causes inflammation and sores in the digestive tract. The study evaluates a new treatment approach using autologous regulatory T-cells, which are special immune cells taken from the patient’s own body, modified and expanded in a laboratory, and then returned through an intravenous infusion.

The treatment involves collecting the patient’s own immune cells, specifically T-cells that help regulate the immune system. These cells are processed in a laboratory to increase their numbers and then given back to the patient through an intravenous infusion. The treatment, known as Treg therapy, will be administered over a period of two months.

The purpose of this study is to determine if this cell therapy can help achieve remission in people with ulcerative colitis, meaning a reduction in symptoms such as bleeding and frequent bowel movements. The study will monitor patients for 12 weeks after receiving the treatment to evaluate its effectiveness. Each patient may receive up to two infusions of the processed immune cells during the study period.